1-12 of 12
Authors: Simon Portsmouth
Journal Article
Heterogeneity of Recent Phase 3 Complicated Urinary Tract Infection Clinical Trials
Open Forum Infectious Diseases, Volume 8, Issue 3, March 2021, ofab045, https://doi.org/10.1093/ofid/ofab045
Published: 02 February 2021
Journal Article
1271. Efficacy and Safety of Cefiderocol and Best Available Therapy in Patients with Serious Infections Caused by Carbapenem-Resistant Gram-Negative Infections: Results of the Pathogen-Focused Phase 3 CREDIBLE-CR Study
Open Forum Infectious Diseases, Volume 7, Issue Supplement_1, October 2020, Pages S652–S653, https://doi.org/10.1093/ofid/ofaa439.1455
Published: 31 December 2020
Journal Article
1292. Safety Profile of the Novel Siderophore Cephalosporin Cefiderocol in Randomized Phase 2 and Phase 3 Clinical Studies of Serious Gram-Negative Infections
Open Forum Infectious Diseases, Volume 7, Issue Supplement_1, October 2020, Pages S661–S662, https://doi.org/10.1093/ofid/ofaa439.1475
Published: 31 December 2020
Journal Article
1311. Intrapulmonary Pharmacokinetics of Cefiderocol in Hospitalized and Ventilated Patients Receiving Standard of Care Antibiotics for Bacterial Pneumonia
Open Forum Infectious Diseases, Volume 7, Issue Supplement_1, October 2020, Page S668, https://doi.org/10.1093/ofid/ofaa439.1493
Published: 31 December 2020
Journal Article
1316. Pharmacokinetic/Pharmacodynamic Analyses of Cefiderocol in Critically Ill Patients
Open Forum Infectious Diseases, Volume 7, Issue Supplement_1, October 2020, Pages S669–S670, https://doi.org/10.1093/ofid/ofaa439.1498
Published: 31 December 2020
Journal Article
666. Efficacy and Safety of Cefiderocol According to Renal Impairment in Patients With Complicated Urinary Tract Infection (cUTI) in a Phase 2 Study
Open Forum Infectious Diseases, Volume 6, Issue Supplement_2, October 2019, Page S305, https://doi.org/10.1093/ofid/ofz360.734
Published: 23 October 2019
Journal Article
1473. Structured Patient Interview in Complicated Urinary Tract Infections to Assess Clinical Outcomes vs. Investigator’s Evaluation in the APEKS-cUTI Study
Open Forum Infectious Diseases, Volume 6, Issue Supplement_2, October 2019, Page S537, https://doi.org/10.1093/ofid/ofz360.1337
Published: 23 October 2019
Journal Article
LB16. Phase 3 Trial of Baloxavir Marboxil in High-Risk Influenza Patients (CAPSTONE-2 Study)
Open Forum Infectious Diseases, Volume 5, Issue suppl_1, November 2018, Pages S764–S765, https://doi.org/10.1093/ofid/ofy229.2190
Published: 26 November 2018
Journal Article
1521. Heterogeneity of Recent Phase 3 cUTI Clinical Trials with New Antibiotics
Open Forum Infectious Diseases, Volume 5, Issue suppl_1, November 2018, Page S472, https://doi.org/10.1093/ofid/ofy210.1350
Published: 26 November 2018
Journal Article
1645. Exploring Clinical and Antiviral Efficacy of Baloxavir Marboxil in a Phase 3, Randomized, Double-Blind, Placebo- and Active-Controlled Study of Otherwise Healthy Adults/Adolescents in Seasonal Influenza: Impact on Regional Participants, Treatment Time and Influenza Type B Virus Infection (CAPSTONE-1 Study)
Open Forum Infectious Diseases, Volume 5, Issue suppl_1, November 2018, Page S48, https://doi.org/10.1093/ofid/ofy209.115
Published: 26 November 2018
Journal Article
Clinical Response of Cefiderocol Compared with Imipenem/Cilastatin in the Treatment of Adults with Complicated Urinary Tract Infections with or without Pyelonephritis or Acute Uncomplicated Pyelonephritis: Results from a Multicenter, Double-blind, Randomized Study (APEKS-cUTI)
Open Forum Infectious Diseases, Volume 4, Issue suppl_1, Fall 2017, Pages S537–S538, https://doi.org/10.1093/ofid/ofx163.1399
Published: 04 October 2017
Journal Article
Cap-dependent Endonuclease Inhibitor S-033188 for the Treatment of Influenza: Results from a Phase 3, Randomized, Double-Blind, Placebo- and Active-Controlled Study in Otherwise Healthy Adolescents and Adults with Seasonal Influenza
Open Forum Infectious Diseases, Volume 4, Issue suppl_1, Fall 2017, Page S734, https://doi.org/10.1093/ofid/ofx180.001
Published: 04 October 2017
